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ABSTRACT 
Vaccines were the result of trial and error research until molecular biology and genetic engineering 
made possible the creation of many new and improved vaccines. New vaccines need to be 
inexpensive, easily administered, and capable of being stored and transported without refrigeration; 
without these characteristics, developing countries find it difficult to adopt vaccination as the central 
strategy for preventing their most devastating diseases. Edible vaccines hold great promise as a cost-
effective, easy-to-administer, easy-to-store, fail-safe and socio culturally readily acceptable vaccine 
delivery system, especially for the poor developing countries. It involves introduction of selected 
desired genes into plants and then inducing these altered plants to manufacture the encoded 
proteins. Introduced as a concept about a decade ago, it has become a reality today. A variety of 
delivery systems have been developed. Initially thought to be useful only for preventing infectious 
diseases, it has also found application in prevention of autoimmune diseases, birth control, cancer 
therapy, etc. Edible vaccines are currently being developed for a number of human and animal 
diseases. There is growing acceptance of transgenic crops in both industrial and developing 
countries. Resistance to genetically modified foods may affect the future of edible vaccines. Plants are 
capable of producing recombinant antigens that undergo similar post translational modifications as 
their mammalian-derived counterparts and in contrast to bacterial expression systems. 
KEYWORDS: Bacterial expression, Edible vaccines, Transgenic. 
INTRODUCTION 
Vaccines have been revolutionary for the 
prevention of infectious diseases. Despite worldwide 
immunization of children against the six devastating 
diseases, 20% of infants are still left un-immunized; 
responsible for approximately two million unnecessary 
deaths every year, especially in the remote and 
impoverished parts of the globe. This is because of the 
constraints on vaccine production, distribution and 
delivery.[3] One hundred percent coverage is desirable, 
because un-immunized populations in remote areas can 
spread infections and epidemics in the immunized 
"safe" areas, which have comparatively low herd 
immunity. For some infectious diseases, immunizations 
either do not exist or they are unreliable or very 
expensive. Immunization through DNA vaccines is an 
alternative but is an expensive approach, with 
disappointing immune response. [12] Hence the search is 
on for cost-effective, easy to administer, easy-to-store, 
fail safe and socioculturally readily acceptable vaccines 
and their delivery systems. As Hippocrates said, "Let 
thy food be thy medicine," scientists suggest that plants 
and plant viruses can be genetically engineered to 
produce vaccines against diseases such as dental caries; 
and life-threatening infections like diarrhea, AIDS, etc. 
This is the concept of edible vaccines. The following 
discussion will address issues relating to their 
commercial development, especially their usefulness in 
preventing infectious diseases in developing 
countries.[11] 
By the late 1990s an international campaign to 
immunize all the world’s children against six 
devastating diseases was reportedly reaching 80 
percent of infants (up from about 5 percent in the mid-
1970s) and was reducing the annual death toll from 
those infections by roughly three million.[15] Yet these 
victories mask tragic gaps in delivery. The 20 percent of 
infants still missed by the six vaccines against 
diphtheria, pertussis (whooping cough), polio, measles, 
tetanus and tuberculosis account for about two million 
unnecessary deaths each year, especially in the most 
remote and impoverished parts of the globe. Upheavals 
in many developing nations now threaten to erode the 
advances of the recent past, and millions still die from 
infectious diseases for which immunizations are 
nonexistent, unreliable or too costly.[21] 
When environmental or social disasters 
undermine sanitation systems or displace communities 
bringing people with little immunity into contact with 
carriers infections that have been long gone from a 
population can come roaring back. Further, as 
international travel and trade make the earth a smaller 
place, diseases that arise in one locale are increasingly 
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popping up continents away. Until everyone has routine access to vaccines, no one will be entirely safe.  
 
Figure 1: Need for Edible Vaccines 
The Children's Vaccine Initiative 
In 1990, translation of scientific advancements 
into the new vaccines needed by developing countries 
was lagging. At the World Summit for Children in New 
York that year, a consortium of philanthropic, health, 
and intergovernmental organizations urged the world 
to harness new technologies to advance the 
immunization of children. The resulting Children's 
Vaccine Initiative (CVI) recognized the role that new 
technologies might play in improving current vaccines 
and developing new ones.[1] 
In 1992, WHO estimated that three to five 
million children's lives could be saved each year if new 
vaccines were available to control or prevent commonly 
occurring infectious diseases. Diarrheal and respiratory 
infections are major causes of infant mortality in the 
developing world. CVI focused attention on the need to 
exploit technologies that would make vaccines-both 
their production and use-less expensive and more 
reliable, especially for the developing world. The 
Initiative emphasized the importance of oral vaccines 
because they eliminate the need for needles and 
syringes with their accompanying costs and risks.[14] 
The pain of injections and the reaction of children is 
often a reason why subsequent vaccination visits are 
missed. (Oral vaccines may also induce mucosal 
immunity, creating a barrier in the gut, lungs, and 
urogenital tract that can block infection before the body 
must rely on a systemic response.) CVI also promoted 
development of multicomponent vaccines in which a 
antigens against several infectious agents could be 
delivered simultaneously, thus simplifying 
administration.[16] Heat-stable vaccines, also advocated 
by CVI, would not need refrigeration-the traditional 
cold chain-which currently limits success and coverage 
in developing countries. Each of these desired features-
low costs, improved reliability, elimination of injections, 
mucosal immunity, multicomponent vaccines, and heat-
stability can potentially be found in plant-based 
vaccines. 
Concept of Edible Vaccines    
As our understanding grows of how the 
immune system recognizes individual proteins to which 
it has been exposed before, other recombinant subunit 
vaccines will be developed offering exciting disease 
prevention opportunities. But recombinant vaccine 
production is likely to remain dependent on costly 
fermentation and protein purification technology. 
Moreover, vaccines produced this way often need to be 
refrigerated and injected.[11] Unfortunately, while 
research on which proteins make effective vaccines and 
on the genes that control their production proceeds in 
many laboratories, much less research has been 
devoted to the organisms in which to express these 
genes-microbes or plants that will produce the 
immunogenic protein in large quantities.[21] The 
recombinant HBV vaccine produced by yeast cells 
grown in large fermenters provides a benchmark of 
efficacy and safety for vaccines produced in 
recombinant organisms. A transgenic plant, that is 
plants in which genes from other species have been 
introduced, may prove to be an equally useful way to 
produce proteins encoded by specific genes. [22] 
Creating edible vaccines involves introduction 
of selected desired genes into plants and then inducing 
these altered plants to manufacture the encoded 
proteins. This process is known as "transformation," 
and the altered plants are called "transgenic plants." 
Like conventional subunit vaccines, edible vaccines are 
composed of antigenic proteins and are devoid of 
pathogenic genes. Thus, they have no way of 
establishing infection, assuring its safety, especially in 
immune compromised patients.[23] Conventional 
subunit vaccines are expensive and technology-
intensive, need purification, require refrigeration and 
produce poor mucosal response. In contrast, edible 
vaccines would enhance compliance, especially in 
children and because of oral administration, would 
eliminate the need for trained medical personnel. Their 
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production is highly efficient and can be easily scaled 
up. They are cheaper, sidestepping demands for 
purification (single dose of hepatitis-B vaccine would 
cost approximately 23 paisa), grown locally using 
standard methods and do not require capital-intensive 
pharmaceutical manufacturing facilities. Mass-
indefinite production would also decrease dependence 
on foreign supply. They are heat-stable; do not require 
cold-chain maintenance; can be stored near the site of 
use, eliminating long-distance transportation. Non-
requirement of syringes and needles also decreases 
chances of infection.[7] Fear of contamination with 
animal viruses - like the mad cow disease, which is a 
threat in vaccines manufactured from cultured 
mammalian cells - is eliminated, because plant viruses 
do not infect humans. 
Edible vaccines activate both mucosal and 
systemic immunity, as they come in contact with the 
digestive tract lining. This dual effect would provide 
first-line defense against pathogens invading through 
mucosa, like Mycobacterium tuberculosis and agents 
causing diarrhea, pneumonia, STDs, HIV, etc.. Edible 
vaccines would also be suitable against neglected/rare 
diseases like dengue, hookworm, rabies, etc.[10] They 
may be integrated with other vaccine approaches and 
multiple antigens may also be delivered. Various foods 
under study are banana, potato, tomato, lettuce, rice, 
etc. Edible vaccines are currently being developed for a 
number of human and animal diseases, including 
measles, cholera, foot and mouth disease and hepatitis 
B, C and E. [15] 
Release Mechanism 
The antigens in transgenic plants are delivered 
through bio-encapsulation, i.e. the tough outer wall of 
plant cells, which protects them from gastric secretions 
and finally break up in the intestines. [1] The antigens 
are released, taken up by M cells in the intestinal lining 
that overlie peyer's patches and gut-associated 
lymphoid tissue (GALT), passed on to macrophages, 
other antigen-presenting cells; and local lymphocyte 
populations, generating serum IgG, IgE responses, local 
IgA response and memory cells, which would promptly 
neutralize the attack by the real infectious agent. [2] 
Preparation of Edible Vaccines 
 
Figure 2: Process for preparation of Edible Vaccines [1] 
Introduction of foreign DNA into plant's 
genome can either be done by bombarding embryonic 
suspension cell cultures using gene-gun or more 
commonly through Agrobacterium tumefaciens, a 
naturally occurring soil bacterium, which has the ability 
to get into plants through some kind of wound (scratch, 
etc.). It possesses a circular "Ti plasmid" (tumor 
inducing), which enables it to infect plant cells, 
integrate into their genome and produce a hollow 
tumor (crown gall tumor), where it can live.[3] This 
ability can be exploited to insert foreign DNA into plant 
genome. But prior to this, the plasmid needs to be 
disarmed by deleting the genes for auxin and cytokinin 
synthesis, so that it does not produce tumor. Genes for 
antibiotic resistance are used to select out the 
transformed cells and whole plants, which contain the 
foreign gene; and for expressing the desired product, 
which can then be regenerated from them. The DNA 
integrates randomly into plant genome, resulting in a 
different antigen expression level for each independent 
line, so that 50-100 plants are transformed together at a 
time, from which one can choose the plant expressing 
the highest levels of antigen and least number of 
adverse effects.[4] Reducing this time to 6-8 weeks is 
currently under investigation. Some antigens, like viral 
capsid proteins, have to self-assemble into VLPs (virus-
like particles). VLPs mimic the virus without carrying 
DNA or RNA and therefore are not infectious. Each 
single antigen expressed in plants must be tested for its 
proper assembly and can be verified by animal studies, 
Western blot; and quantified by Enzyme-Linked 
Immune Sorbent Assay (ELISA).[3] 
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Figure 3: Flowchart depicting process of preparation of Edible Vaccines 
Generations of Edible Vaccines 
Successful expression of foreign genes in plant 
cells and/or its edible portions has given a potential to 
explore further and expand the possibility of 
developing plants expressing more than one antigenic 
protein. Multicomponent vaccines can be obtained by 
crossing two plant lines harboring different antigens. [2] 
Adjuvants may also be co-expressed along with the 
antigen in the same plant. B subunit of Vibrio cholerae 
toxin (VC-B) tends to associate with copies of itself, 
forming a doughnut-shaped five-member ring with a 
hole in the middle. This feature can bring several 
different antigens to M cells at one time - for example, a 
trivalent edible vaccine against cholera, ETEC 
(Enterotoxigenic E.coli) and rotavirus could 
successfully elicit significant immune response to all 
three. Global alliance for vaccines and immunization 
(GAVI) accords very high priority to such combination 
vaccines for developing countries. [5] 
In the course of evaluation of transgenic plants as a new 
means of vaccine production, three separate courses 
were pursued: 
 First, experiment was done to determine the 
capacity of plants to produce foreign proteins that 
retain antigenic characteristics necessary to induce 
immunity.  
 Second, evaluation of the immunogenicity of 
ingested plant-derived proteins was done. 
 Third, an appropriate food crop that could be used 
for both production and distribution of vaccines, 
with attention to the needs of the developing world 
was sought. 
 
 
Various Strategies 
Approaches to mucosal vaccine formulation 
include (i) gene fusion technology, creating non-toxic 
derivatives of mucosal adjuvants; (ii) genetically 
inactivating antigens by deleting an essential gene; (iii) 
co-expression of antigen and a cytokine, which 
modulates and controls mucosal immune response; and 
(iv) genetic material itself, which allows DNA/RNA 
uptake and its endogenous expression in the host 
cell.[25] Various mucosal delivery systems include 
biodegradable micro- and nanoparticles, liposomes, live 
bacterial/viral vectors and mucosal adjuvants. "Prime-
boost" strategy combines different routes of 
administration and vaccine types, especially where 
multiple antigens or doses are required. For example, a 
single parenteral dose of MV-H DNA (measles virus 
haemagglutinin) followed by multiple oral MV-H 
boosters could induce greater quantities of MV-
neutralizing antibodies than with either vaccine 
alone.[26] 
Requirements of "Vector" plants 
Some of the reasons for the requirements of vector 
plants are: 
 Able to produce functional copies of the specified 
protein(s). 
 Able to produce a substantial amount per cell (up 
to 0.05% of total soluble proteins) of the specified 
proteins. 
 Able to grow in volume (plants sometimes grow 
poorly when they start producing large amounts of 
foreign proteins).  
01
•Introduction of foreign DNA into plant's genome can either be done by bombarding
embryonic suspension cell cultures using gene-gun or more commonly through
Agrobacterium tumefaciens , a naturally occurring soil bacterium, which has the
ability to get into plants through some kind of wound (scratch, etc.).
02
•Genes for antibiotic resistance are used to select out the transformed cells and
whole plants, which contain the foreign gene; and for expressing the desired
product, which can then be regenerated from them. The DNA integrates randomly
into plant genome, resulting in a different antigen expression level for each
independent line, so that 50-100 plants are transformed together at a time, from
which one can choose the plant expressing the highest levels of antigen and least
number of adverse effects
03
•Some antigens, like viral capsid proteins, have to self-assemble into VLPs (virus-
like particles). VLPs mimic the virus without carrying DNA or RNA and therefore
are not infectious. Each single antigen expressed in plants must be tested for its
proper assembly and can be verified by animal studies, Western blot; and quantified
by Enzyme-Linked Immune Sorbent Assay (ELISA).
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 Able to produce a defined amount of the specified 
protein(s) to ensure that any given amount of 
vaccine food provides a predictable dose of antigen. 
Regulatory agencies will not approve vaccines with 
variable dosing. 
 Able to be grown locally. 
 Able to be regenerated readily without the growers 
having to purchase more seeds or plants year after 
year. 
 Other components of transgenic plants may have 
inhibiting or promoting effects on immunogenicity. 
 Allergy to antigens that until now only have been 
applied parenterally. 
 Possible recombination events of viral sequences of 
plant and animal pathogenic viruses. 
Advantages 
 Safer than those produced in animal tissues 
because the chances of unknown human pathogens 
hitching a ride would be extremely small. 
 Economical advantages (obstacle to interests of 
vaccine industry). 
 Cheap to produce. Cost per dose would be low. 
 No refrigeration required by vaccine-containing 
seeds or dried leaves, a significant advantage in 
developing countries. 
 No injection required and there is no risk of 
accidental parenteral infections from contaminated 
needles. 
 Elicit mucosal immunity in addition to systemic 
immunity: anyway nasal immunization is more 
efficient than oral immunization at stimulating 
effector immunity in the reproductive tract. 
Scientific Challenges 
There are many questions which need to be 
answered before developing a plant-based vaccine. 
Three successful human clinical trials have shown that 
adequate doses of antigen can be achieved with plant-
based vaccines. [1] To determine the right dosage, one 
need to consider the person's weight, age; fruit/plant's 
size, ripeness and protein content. The amount to be 
eaten is critical, especially in infants, who might spit it, 
eat a part or eat it all and throw it up later. Too low a 
dose would fail to induce antibodies and too high a dose 
would, instead, cause tolerance. [21] Concentrating the 
vaccine into a teaspoon of baby food may be more 
practical than administering it in a whole fruit. The 
transformed plants can also be processed into pills, 
puddings, chips, etc. Regulatory concerns would include 
lot-to-lot consistency,  
Attempts at boosting the amount of antigens 
often lead to stunted growth of plants and reduced 
tuber/fruit formation, as too much m-RNA from the 
transgene causes gene-silencing in plant genome. 
uniformity of dosage and purity. [23] 
Some of the techniques to overcome these limitations 
are: 
 Optimization of coding sequence of bacterial/viral 
genes for expression as plant nuclear genes.  
 Expression in plastids.  
 Plant viruses expressing foreign genes.  
 Coat-protein fusions.  
 Viral-assisted expression in transgenic plants and 
promoter elements of bean yellow dwarf virus 
with reporter genes GUS (β -glucuronidase) and 
GFP (green fluorescent protein), substituted later 
with target antigen genes. [18] 
To enhance immunogenicity, mucosal 
adjuvants, better targeted to the immune system, may 
be used, like molecules that bind to M cells in the 
intestine lining and pass them to immune cells. These 
include CT-B (Cholera toxin - B subunit), LT-B (ETEC), 
mammalian/viral immunomodulators and plant-
derived secondary metabolites. To decrease toxicity 
and allergic potential, mutant forms of E. coli -labile 
toxin, like LT-K63 and LT-R72 and hinge cleavage 
mutant LT-G192, are used. Another challenge would be 
in dealing with diseases caused by multiple serotypes 
(dengue) or by complex parts from different life cycles 
of parasites (malaria) or by rapidly mutating organisms 
(HIV, trypanosomes, influenza). 
Non-Scientific Challenges 
Presently, small technology companies are 
undertaking most research, as edible vaccines are 
targeted to markets of developing nations. Large 
companies are more interested in livestock market than 
human application.[13] Only few international aid 
organizations and some national governments are 
rendering support, but the effort remains largely 
underfunded. Some of the companies funding edible 
vaccines research have failed to click due to lack of 
investors' confidence in returns on investments in 
genetically modified (GM) foods. There is also a lack of 
research and development (R&D) personnel in the 
pharmaceutical companies. In addition, the 
recombinant (injectable) vaccines against diphtheria, 
tetanus, etc. are so cheap now, that there would be little 
incentive to develop edible vaccines for them. [19] 
Clinical Trials 
Antigen expression in plants has been 
successfully shown in the past, like LT-B (ETEC) in 
tobacco and potato, rabies virus-G protein in tomato, 
HBsAg in tobacco and potato, norwalk virus in tobacco 
and potato; CT-B (Vibrio cholerae) in potato. Ethical 
considerations usually preclude clinical trials from 
directly assessing protection, except in a few cases. In 
contrast, veterinary researchers can assess immune 
protection more directly. [8] 
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Examples 
 
Table 1: Examples of Recombinant vaccines from different plants [29]
CLOSTRIDIUM TETANI VACCINE  
Transgenic plants: stable integration of a gene into the 
plant nuclear or chloroplast genome can transform 
higher plants (e.g. tobacco, potato, tomato, banana) into 
bioreactors for the production of subunit vaccines for 
oral (but also for parental) administration. This can also 
be achieved by using recombinant plant viruses as 
transient expression vectors in infected plant. [15] 
Tobacco (Nicotiana spp.): easy to manipulate, but high 
levels of toxic alkaloids in the leaves don't allow studies 
on animal feeding. For experimental purposes antigens 
have to be substantially purified and then tested for 
their immunogenicity. [17] 
Potato (Solanum tuberosum): easily propagated from 
"eyes", generated within a few months, stored for long 
periods without refrigeration, but they have to be 
cooked to be palatable (apart from toleration by 
volunteers. Anyway mice accept raw potato tubers and 
further some kinds of potatoes are actually eaten raw in 
South America populations), and heating can 
sometimes (but not always) denature antigens. [18] 
Banana (Musa acuminate): need no cooking, but 
banana trees take at least 2 years to mature, the fruit 
has low protein content and spoils fairly rapidly after 
ripening. 
Tomato (Lycopersicon esculentum): grow more 
quickly, but their fruit too has low protein content. 
Lettuce (Lactuca sp.)  
Carrot (Daucus carota) 
Peanut (Arachis hypogaea)  
Rice (Oryza sativa) 
Wheat (Triticum aestivum) 
Corn/Maize (Zea mays subsp. mays) (if for 
animal vaccines: alfalfa, grains and beans). Transgenic 
corn is particularly attractive for this purpose since the 
recombinant antigen is stable and homogeneous, and 
corn can be formulated in several edible forms without 
destroying the cloned antigen.[25] 
Lupine (Lupinus sp.) 
Thale cress (Arabidopsis thaliana) 
Soybean seeds (Glycine max) 
Corn / Maize seeds (Zea mays subsp. mays) 
Other Examples 
Human pathogens: 
Viruses: 
Anti-Norwalk virus vaccine: capsid protein in GM 
tobacco and potatoes. 
Anti-rotaviruses vaccine 
VP7 DNA vaccine can induce high levels of IgG 
in mice but cannot protect mice against challenge. Mice 
immunized with transgenic potato successfully elicited 
serum IgG and mucosal IgA specific for VP7. The 
mucosal IgA titer was as high as 1000, while serum IgG 
titer was only 600. Neutralizing assays indicate that IgA 
could neutralize rotavirus. [13] 
Cholera toxin (CT) B and A2 subunit 
complementary DNAs (cDNAs) fused to a rotavirus 
enterotoxin and enterotoxigenic Escherichia coli 
fimbrial antigen genes and transferred into potato. 
Fusion antigens are synthesized in transformed tuber 
tissues and assembled into cholera holotoxin-like 
structures that retained enterocyte-binding affinity.[27] 
Anti-HAV vaccine: the construction of the plant 
expression vector pBI121-A was reported, which 
contained a fusion gene encoding hepatitis A capsid 
proteins. The gene was located between the left and 
right Ti border sequences under the control of 
CaMV35S promoter. The vector was identified via PCR 
and restriction enzyme analysis and was introduced 
into Agrobacterium tumerifacience LBA4404.The 
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transgenic Citrus plants were produced by 
Agrobacterium-mediated transformation of epicotyl 
segments. [28] 
Anti-HBV vaccine: HBsAg using Agrobacterium 
mediated transformation in transgenic 
Potatoes accumulate intracellular as tubular 
structures, with a complex size distribution, differing 
substantially from the virus-like particle (VLP) 
preparations of the current commercial vaccines: 
natural bio encapsulation of the antigen may provide 
protection from degradation in the digestive tract until 
plant cell degradation occurs near an immune effector 
site in the gut. Extensive disulfide-bond cross-linking, 
which is important for immunogenicity, was evident 
and 21-37% of total HBsAg protein displayed epitopes 
which correlate with vaccine potency. [26] 
Tomatoes: Arntzen and his colleagues are focusing on 
creating them and converting them into pills. [3] 
Banana cv. Rasthali (AAB): 4 different expression 
cassettes (pHBS, pHER, pEFEHBS and pEFEHER) were 
utilized to optimize the expression of HBsAg in banana. 
The transgenic nature of the plants and expression of 
the antigen was confirmed by PCR, Southern 
hybridization and RT-PCR. The expression levels of the 
antigen in the plants grown under in vitro conditions as 
well as the green house hardened plants were 
estimated by ELISA for all the four constructs. 
Maximum expression level of 38 ng/g F.W. of leaves 
was noted in plants transformed with pEFEHBS grown 
under in vitro conditions, whereas pHER transformed 
plants grown in the green house showed the maximum 
expression level of 19.92 ng/g F.W. of leaves. Higher 
mAb binding of 67.87% of the antigen was observed 
when it was expressed with a C-terminal ER retention 
signal. [27] 
Anti-HPVs vaccine: Transgenic tobacco and potato 
plants carrying the HPV type 16 major structural gene 
L1 under the control of the cauliflower mosaic virus 35S 
promoter. The plant-derived L1 protein displayed 
conformation-specific epitopes and assembled into 
virus-like particles. Furthermore, we did not find any 
indications of protein modification of the L1 protein 
produced in plants. Plant-derived L1 was as 
immunogenic as L1 expressed in baculovirus-infected 
insect cells. Feeding of tubers from transgenic potatoes 
to mice induced an anti-L1 antibody response in 3 out 
of 24 mice, although this response was only transient in 
two of the mice. However an anti-L1 response was 
primed in about half of the 24 animals. [19] 
Anti-HIV-1 vaccine: chimeric virus particles (CVPs) in 
which gp41 are expressed as N-terminal translational 
fusion with the potato virus X (PVX) coat protein. 
Transgenic tomatoes expressing the Tat protein. Two 
independent plants testing positives to transgene 
detection analysis were selected and grown to maturity. 
Monoclonal antibodies against tat recognized a protein 
of the expected size. Interestingly, expression of Tat 
seemed to be toxic to the plant as in all cases the fruit 
presented underdeveloped reproductive structures and 
no seeds. 9 groups of ten pathogen-free male mice were 
primed either, orally, intraperitoneally (i.p.) or 
intramuscularly (i.m.) with 10 mg of tomato fruit 
extract derived from transgenic or wild type plants and 
with 10 mg of Tat86 recombinant protein. [27] 
Non-human pathogens: Anti-foot-and-mouth disease 
virus (FMDV) vaccine:  transgenic potatoes plants 
containing the VP1 gene cloned under the regulatory 
activity of either a single (pRok2) copy of the S35 
cauliflower mosaic virus (CaMV 35S) promoter:  use of 
double CaMV 35S promoter does not cause a significant 
increase in the level of the VP1 expressed. 
Anti-infectious bronchitis virus (IBV) Vaccine: S1 
glycoprotein in potatoes. [25] 
Anti-rabbit hemorrhagic disease virus (RHDV)  
Vaccine: major structural protein VP60 in transgenic 
tubers of potatoes plants.  
Anti-SIV Vaccine: cholera toxin B subunit (CTB) was 
linked 5' to the simian immunodeficiency virus 
(SIVmac) Gag p27 capsid gene (CTB-Gag). The fusion 
gene was transferred into potato cells by 
Agrobacterium tumefaciens-mediated transformation 
methods and transformed plants regenerated. The CTB-
Gag gene fusion was detected in transformed potato 
leaf genomic DNA by polymerase chain reaction-
mediated DNA amplification. The results of immunoblot 
analysis with anti-CTB and anti-Gag antibodies verified 
the synthesis of biologically active CTB-Gag fusion 
protein in transformed leaf and tuber tissues. Synthesis 
and assembly of the CTB-Gag fusion protein into 
oligomeric structures of pentamer size was confirmed 
by GM1-ganglioside-enzyme-linked immunosorbent 
assay (GM1-ELISA) of transformed potato tuber tissue 
extracts.  
The Future of Edible Vaccines 
Vaccines have been one of the most far-
reaching and important public health initiatives of the 
20th century. The future of edible vaccines is bright as 
it holds great promise as a cost-effective, easy-to-
administer, easy-to-store, fail-safe and socio-culturally 
readily acceptable vaccine delivery system, especially 
for the poor developing countries. It involves 
introduction of selected desired genes into plants and 
then inducing these altered plants to manufacture the 
encoded proteins. Introduced as a concept about a 
decade ago, it has become a reality today. A variety of 
delivery systems have been developed.[26] Initially 
thought to be useful only for preventing infectious 
diseases, it has also found application in prevention of 
autoimmune diseases, birth control, cancer therapy, etc. 
Edible vaccines are currently being developed for a 
number of human and animal diseases. There is 
growing acceptance of transgenic crops in both 
industrial and developing countries. Resistance to 
genetically modified foods may affect the future of 
edible vaccines. They have passed the major hurdles in 
the path of an emerging vaccine technology. [27,28] The 
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studies completed so far in animals and people have 
provided a proof of principle; they indicate that the 
strategy is feasible. Yet many issues must still be 
addressed. Researchers are also grappling with the 
reality that plants sometimes grow poorly when they 
start producing large amounts of a foreign protein. [28] 
One solution would be to equip plants with regulatory 
elements that cause antigen genes to turn on--that is, 
give rise to the encoded antigens-only at selected times 
(such as after a plant is nearly fully grown or is exposed 
to some outside activator molecule) or only in its edible 
regions. This work is progressing.  
Few credible studies are there on the safety of 
GM foods. By facilitating horizontal gene transfer/ 
recombination, genetic engineering may contribute to 
emergence and re-emergence of infectious, drug-
resistant diseases, rise of autoimmune diseases, cancers 
and reactivation of dormant viruses. Bacteria may take 
up transgenic DNA in food in human gut. [15] There is 
also the risk of creating altogether new strains of 
infectious agents, like super viruses. By DNA shuffling, 
geneticists can create in a matter of minutes in the 
laboratory, millions of recombinant viruses that have 
never existed in billions of years of evolution.[26] This 
may be misused for the intentional creation of bio-
weapons.[28] Feeding GM products like maize to animals 
may also carry risks, not just for the animals but also for 
human beings consuming the animal products.  
Increase in global area utilized in cultivating 
transgenic crops from 1.7 to 44.2 million hectares from 
1996 to 2000 and the number of countries growing 
them from 6 to 13 reflects the growing acceptance of 
transgenic crops in both industrial and developing 
countries. At least 350 genetically engineered 
pharmaceutical products are currently under 
development in the United States and Canada. Edible 
vaccines offer major economic and technical benefits in 
the event of bioterrorism, as their production can be 
easily scaled up for millions of doses within a limited 
period of time (smallpox, anthrax, plague, etc.).  
Future Plans 
Edible plant-derived vaccine may lead to a 
future of safer and more effective immunization. They 
would overcome some of the difficulties associated with 
traditional vaccines, like production, distribution and 
delivery and they can be incorporated into the 
immunization plans.[22] They have passed the major 
hurdles in the path of an emerging vaccine technology. 
Before becoming a reality, the technical obstacles, 
though all seem surmountable, need to be overcome. 
However, with limited access to essential health care in 
much of the world and with the scientific community 
still struggling with complex diseases like HIV, malaria, 
etc, a cost-effective, safe and efficacious delivery system 
in the form of edible vaccines will become an essential 
component in our disease-prevention arsenal.  
CONCLUSION 
Edible vaccines are currently being developed 
for a number of human and animal diseases. There is 
growing acceptance of transgenic crops in both 
industrial and developing countries. Resistance to 
genetically modified foods may affect the future of 
edible vaccines. Plants are capable of producing 
recombinant antigens that undergo similar post 
translational modifications as their mammalian-derived 
counterparts and in contrast to bacterial expression 
systems. Yet many issues must still be addressed. 
Researchers are also grappling with the reality that 
plants sometimes grow poorly when they start 
producing large amounts of a foreign protein. The 
studies completed so far in animals and people have 
provided a proof of principle; they indicate that the 
strategy is feasible and beneficial for future use in 
treatment of various diseases. 
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